You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Article Text

Article menu

Download PDFPDF

XML
Correction
Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

https://doi.org/10.1136/jitc-2020-001622corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Allouchery M, Lombard T, Martin M, the French Network of Regional Pharmacovigilance Centers, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020;8:e001622. doi: 10.1136/jitc-2020-001622

    This paper has been updated since first published to revise affiliation 10 to ‘+Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France’.